Long term disease free survival with multimodal therapy in small cell bladder cancer

Eur J Med Res. 2016 Oct 13;21(1):40. doi: 10.1186/s40001-016-0234-9.

Abstract

Background: Small cell bladder cancer (SCBC) is an aggressive subtype accounting for less than 1 % of all bladder malignancies associated with rapid progression, early metastases formation and high mortality rates.

Case presentation: We present an unusual long term disease free survival of a 60 year-old man who was diagnosed with SCBC two and a half years ago. He underwent four cycles of cisplatin/etoposide chemotherapy as well as a prophylactic whole-brain radiotherapy followed by a radical cystoprostatectomy and ileal neobladder with extended pelvic lymphadenectomy. Since 33 months the patient is now recurrence-free.

Conclusion: In this case report, we were able to show that early multimodal therapy results in long term disease free survival, thus we highly recommend neoadjuvant chemotherapy as a part of multimodal management of a primary metastases-free, localized and surgically resectable SCBC.

Keywords: Disease free survival; Multimodal therapy; Neoadjuvant chemotherapy; Small cell bladder cancer.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Small Cell / diagnostic imaging
  • Carcinoma, Small Cell / mortality
  • Carcinoma, Small Cell / therapy*
  • Cisplatin / therapeutic use
  • Combined Modality Therapy*
  • Cystectomy
  • Disease-Free Survival
  • Etoposide / therapeutic use
  • Humans
  • Lymph Node Excision
  • Male
  • Middle Aged
  • Prostatectomy
  • Treatment Outcome
  • Urinary Bladder Neoplasms / diagnostic imaging
  • Urinary Bladder Neoplasms / mortality
  • Urinary Bladder Neoplasms / therapy*

Substances

  • Etoposide
  • Cisplatin

Supplementary concepts

  • VP-P protocol